ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "ANCA"

  • Abstract Number: 1524 • 2012 ACR/ARHP Annual Meeting

    The Use of the International Classification of Function, Disability and Health As a Conceptual Framework for Comparison of the Content of Core Outcome Instruments with the Patient Perspective in Vasculitis

    Nataliya Milman1, Peter A. Merkel2, Annelies Boonen3, Lee Strunin4, Ryan Borg4 and Peter Tugwell5, 1Rheumatology, Ottawa Hospital, Riverside Campus, Ottawa, ON, Canada, 2University of Pennsylvania, Philadelphia, PA, 3Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, 4Community Health Sciences, Boston University School of Public Health, Boston, MA, 5Institute of Population Health, Center For Global Health, University of Ottawa, Ottawa General Hospital, Ottawa, ON, Canada

    Background/Purpose: The International Classification of Functioning, Disability and Health (ICF) is a general health model endorsed by the World Health Organization. It describes health along…
  • Abstract Number: 1531 • 2012 ACR/ARHP Annual Meeting

    Comparative Proteomic Analysis of Neutrophils Between Microscopic Polyangiitis and Granulomatosis with Polyangiitis

    Teisuke Uchida1, Kouhei Nagai2, Toshiyuki Sato2, Mitsumi Arito2, Nobuko Iizuka2, Manae Kurokawa2, Naoya Suematsu2, Kazuki Okamoto2, Shoichi Ozaki3 and Tomohiro Kato4, 1Clinical Proteomics and Molecular Medicine, St. Marianna University Graduate School of Medicine,, Kawasaki, Japan, 2Clinical Proteomics and Molecular Medicine, St. Marianna University Graduate School of Medicine, Kawasaki, Japan, 3Division of Rheumatology and Allergy, Department of Internal Medicine, St. Marianna University School of Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, 4Clinical Proteomics and Molecular Medicine, St. Mariannna University Graduate School of Medicine., Kawasaki, Japan

    Background/Purpose: Both microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA) belong to ANCA-associated vasculitis (AAV), in which dysfunction of polymorphonuclear cells (PMN) is thought to…
  • Abstract Number: 1532 • 2012 ACR/ARHP Annual Meeting

    Serum Angiopoietin-2 Level Reflects the Disease Activity and Renal Function in Antineutrophilic Cytoplasmic Antibody-Associated Vasculitis

    Yoko Wada1, Hiroe Sato1, Takeshi Nakatsue1, Shuichi Murakami1, Takeshi Kuroda2, Masaaki Nakano3 and Ichiei Narita1, 1Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan, 2Health Administration Center, Niigata University, Niigata, Japan, 3School of Health Sciences, Faculty of Medicine, Niigata University, Niigata, Japan

    Background/Purpose: Angiopoietin-2 (Ang-2) has emerged as a key mediator of endothelial cell activation. Ang-1 and Ang-2 are antagonistic ligands which bind with similar affinity to…
  • Abstract Number: 2564 • 2012 ACR/ARHP Annual Meeting

    A Risk Score for Predicting Short-Term Incidence of Death or Relapse in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

    Carla Maldini1, Matthieu Resche-Rigon2, David Jayne3, Kerstin Westman4 and Alfred Mahr1, 1Internal Medicine, Hospital Saint-Louis, Paris, France, 2Biostatistics, Hopital Saint-Louis, Paris, France, 3Vasculitis and Lupus Clinic, Addenbrookes Hospital University of Cambridge, Cambridge, United Kingdom, 4Nephrology and Transplantation, Skåne University Hospital Malmö, Lund University, Malmö, Sweden

    Background/Purpose: Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), combining granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), is associated with a substantial risk of relapse or…
  • Abstract Number: 1535 • 2012 ACR/ARHP Annual Meeting

    Genetic Background of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis in a Japanese Population: Association of STAT4 with Myeloperoxidase Antineutrophil Cytoplasmic Antibody-Positive Vasculitis

    Aya Kawasaki1, Naoya Inoue1, Chihiro Ajimi1, Ikue Ito1, Ken-ei Sada2, Shigeto Kobayashi3, Hidehiro Yamada4, Hiroshi Furukawa5, Makoto Tomita6, Takayuki Sumida7, Shigeto Tohma8, Nobuyuki Miyasaka9, Shoichi Ozaki4, Hiroshi Hashimoto10, Hiroshi Makino2, Masayoshi Harigai11 and Naoyuki Tsuchiya1, 1Molecular and Genetic Epidemiology Laboratory, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, 2Department of Medicine and Clinical Science, Okayama University, Okayama, Japan, 3Department of Internal Medicine, Juntendo University Koshigaya Hospital, Tokyo, Japan, 4Internal Medicine, St. Marianna University, Kawasaki, Japan, 5Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan, 6Clinical Research Center, Tokyo Medical and Dental University, Tokyo, Japan, 7Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, 8Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, National Hospital Organization, Sagamihara, Japan, 9Department of Medicine and Rheumatology and Global Center of Excellence Program, Tokyo Medical and Dental University, Tokyo, Japan, 10Juntendo University School of Medicine, Tokyo, Japan, 11Dept of Pharmacovigilance, Tokyo Medical and Dental University, Tokyo, Japan

    Background/Purpose: In antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), geographic difference in the type of vasculitis is well known. While granulomatosis with polyangiitis (GPA) is the…
  • Abstract Number: 2565 • 2012 ACR/ARHP Annual Meeting

    Prevalence of Anti-Neutrophil Cytoplasmic Antibodies in Infective Endocarditis: An Analysis of 109 Cases

    Alfred Mahr1, Frédéric Batteux2, Sarah Tubiana3, Michel Wolff4, Claire Goulvestre2, Thomas Papo5, François Vrtovsnik6, Isabelle Klein7, Bernard Iung8 and Xavier Duval9, 1Internal Medicine, Hospital Saint-Louis, Paris, France, 2Laboratoire d'Immunologie, Hospital Cochin, Paris, France, 3Clinical Investigation, Hospital Bichat, Paris, France, 4Intensive Care Unit, Hospital Bichat, Paris, France, 5Internal Medicine, University Paris-7, INSERM U699, APHP, Bichat Hospital, Paris, France, 6Nephrology, Hospital Bichat, Paris, France, 7Radiology, University Paris-7, APHP, Bichat Hospital, Paris, France, 8Cardiology, Hospital Bichat, Paris, France, 9Infectious Diseases, Hospital Bichat, Paris, France

    Background/Purpose: Anti-neutrophil cytoplasmic antibodies (ANCAs), particularly those directed against proteinase 3 (anti-PR3) or myeloperoxydase (anti-MPO), are considered a highly specific hallmark of ANCA-associated vasculitis. Thus,…
  • Abstract Number: 1536 • 2012 ACR/ARHP Annual Meeting

    Clinical Features of Patients with Anti-Neutrophil Cytoplasmic Autoantibodies Targeting Native Myeloperoxidase Antigen

    Yuji Yamanishi1, Toshiko Ito-Ihara2, Shigeto Kobayashi3, Peter Y. Shane4, Gary S. Firestein5, Hiroshi Hashimoto6 and Kazuo Suzuki7, 1Division of Rheumatology, Hiroshima Rheumatology Clinic, Hiroshima, Japan, 2Department of Clinical Innovative Medicine, Translational Research Center, Kyoto University Hospital, Kyoto, Japan, 3Department of Internal Medicine, Juntendo University Koshigaya Hospital, Tokyo, Japan, 4Tokyo Medical and Dental University, Tokyo, Japan, 5Div of Rheumatology, UCSD School of Medicine, La Jolla, CA, 6Juntendo Tokyo Koto Geriatric Center, Tokyo, Japan, 7National Institute of Infectious Diseases, Tokyo, Japan

    Background/Purpose: ANCA is a useful diagnostic marker in systemic vasculitic disorders with small-vessel involvement, but depending on the particular test used the myeloperoxidase (MPO)-ANCA results…
  • Abstract Number: 2393 • 2012 ACR/ARHP Annual Meeting

    High Mobility Group Box 1 Levels Are Not Associated with Subclinical Carotid Atherosclerosis in Patients with Granulomatosis with Polyangiitis but Are Reduced by Glucocorticoids and Statins

    Alexandre Wagner S. de Souza1, Karina de Leeuw2, Johanna Westra2, Andries J. Smit3, Anne Marijn van der Graaf2, Hans L. A. Nienhuis1, Johan Bijzet2, Pieter C. Limburg4, Coen A. Stegeman5, Marc Bijl6 and Cees G.M. Kallenberg2, 1Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, 2Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, 3Vascular Diseases, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, 4Department of Laboratory Medicine, University Medical Center Groningen, Groningen, Netherlands, 5Nephrology, University Medical Center Groningen, Groningen, Netherlands, 6Rheumatology and Clinical Immunology, Martini Hospital, Groningen, Netherlands

    Background/Purpose: High mobility group box 1 (HMGB1) is a non-histone DNA binding protein that is passively released by dying cells or actively secreted by immunocompetent…
  • Abstract Number: 860 • 2012 ACR/ARHP Annual Meeting

    Interleukin-21, B Cell Activating Factor and Unmethylated CpG Oligodeoxynucleotides Synergize in Promoting Anti-Proteinase 3 Autoantibody Production in Vitro

    Nikola Lepse1, Judith Land2, Abraham Rutgers2, Cees G.M. Kallenberg2, Coen A. Stegeman3, Peter Heeringa1 and Wayel H. Abdulahad2, 1Pathology and Medical Biology, University Medical Center Groningen, Groningen, Netherlands, 2Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, 3Nephrology, University Medical Center Groningen, Groningen, Netherlands

    Background/Purpose: Anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitides (AAV) are characterized by the presence of circulating autoantibodies that are often directed against proteinase 3 (PR3). Although the…
  • Abstract Number: 2379 • 2012 ACR/ARHP Annual Meeting

    Successful Treatment of Churg-Strauss Syndrome with Rituximab

    Christin Dubrau1, Fabian Arndt2, Wolfgang L. Gross and Frank Moosig4, 1Departement of Rheumatology and Clinical Immunology, University Hospital Schleswig-Holstein, Campus Luebeck and Klinikum Bad Bramstedt, Bad Bramstedt, Germany, 2Departement of rheumatology and clinical immunology, University Hospital Schleswig Holstein and Klinikum Bad Bramstedt, Bad Bramstedt, Germany, 3Vasculitis Clinic, Klinikum Bad Bramstedt & University Hospital of Schleswig Holstein, Bad Bramstedt, Germany

    Background/Purpose: Rituximab has recently been shown to be equipotent to cyclophosphamide for induction of remission in generalized ANCA-associated vasculitis. A substantial number of observational pro-…
  • Abstract Number: 2383 • 2012 ACR/ARHP Annual Meeting

    Rituximab As Induction and Maintenance Therapies for ANCA-Associated Vasculitis: A Multicenter Retrospective Study On 80 Patients

    Pierre Charles1, Antoine Néel2, Nathalie Tieulié3, Arnaud Hot4, Grégory Pugnet5, Olivier Decaux6, Isabelle Marie7, Mehdi Khellaf8, Jean-Emmanuel Kahn9, Alexandre Karras10, Jean-Marc Ziza11, Christophe Deligny12, Colas Tchérakian13 and Loic Guillevin14, 1Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France, 2Internal Medicine, Nantes University Hospital, Nantes, France, 3CHU Nice, Nice, France, 4Internal Medicine, Edouard Herriot University Hospital, Lyon, France, 5Department of Internal Medicine, Toulouse University Hospital, University of Toulouse, INSERM UMR 1027, Toulouse, France, 6Department of Internal Medicine, Rennes University Hospital, Rennes, France, 7Service de médecine interne, CHU de Rouen, Rouen, France., Rouen, France, 8Internal Medicine, Service de médecine interne, Université Paris Est Créteil, AP-HP, Hôpital Mondor Créteil, France, Creteil, France, 9Internal Medicine, Foch Hospital, Suresnes, France, 10Nephrology, Hôpital Européen Georges Pompidou, APHP, Paris, France, 11Rheumatology, Croix Saint Simon Hospital, Paris, France, 12Rhumatologie Et Médecine Interne, Centre hospitalier Universitaire de Fort de France, Fort de France, Martinique, 13Service de pneumologie, hôpital Foch, Suresnes, France, 14Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France

    Background/Purpose: Rituximab has been shown to induce remission of ANCA-associated vasculitis (AAV). Our study was undertaken to 1) describe the clinical response of AAV to…
  • Abstract Number: 2700 • 2012 ACR/ARHP Annual Meeting

    A Multi-Center Study of the Appropriateness of Anti-Neutrophilic Cytoplasmic Antibody Testing

    Tarun S. Sharma1, Vikash Sinha2, Vino Unson2, Saurav Acharya3, Sahar Mohammadi2 and Amer Syed2, 1Rheumatology, Geisinger Medical Center, Danville, PA, 2Internal Medicine, Mount.Sinai School of Medicine-Jersey City Medical Center, Jersey City, NJ, 3Internal Medicine, Jersey City Medical Center-Barnabas Health, Jersey City, NJ

    A Multi-Center Study of the Appropriateness of Anti-Neutrophilic Cytoplasmic Antibody TestingBackground/Purpose: Anti Neutrophil Cytoplasmic Antibody (ANCA) test is an Indirect Immunoflorescence test used as an…
  • Abstract Number: 1774 • 2012 ACR/ARHP Annual Meeting

    Identification of Target Antigens of Anti-Endothelial Cell Antibodies in Patients with ANCA-Associated Systemic Vasculitis: A Proteomic Approach

    Alexis Régent1, Hanadi Dib2, Guillaume Bussone1, Mathieu C. Tamby1, Nicolas Tamas2, Christian Federici3, Cédric Broussard3, Loic Guillevin4 and Luc Mouthon1, 1Internal Medicine, Hopital Cochin, Paris, France, 2Université Paris Descartes, Paris, France, 3Institut Cochin, INSERM U1016, CNRS UMR 8104, Université Paris Descartes, Paris, France, 4Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France

    Background/Purpose: Anti-endothelial cell antibodies (AECA) are frequently detected in anti-neutrophil cytoplasm antibodies (ANCA)-associated systemic vasculitis (AAV) and are considered to play pathological roles but their…
  • Abstract Number: 1652 • 2012 ACR/ARHP Annual Meeting

    Rituximab Versus Azathioprine for Maintenance in Antineutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis

    Loic Guillevin1, Christian Pagnoux2, Alexandre Karras3, Chahera Khoutra4, Olivier Aumaitre5, Pascal Cohen6, Francois Maurier7, Olivier Decaux8, Hélène Desmurs-Clavel9, Pierre Gobert10, Thomas Quemeneur11, Claire Blanchard-Delaunay12, Pascal Godmer13, Xavier Puechal14, Pierre-Louis Carron15, Pierre yves Hatron16, Nicolas Limal17, Mohamed Hamidou18, Maize Ducret19, Florence Vende20, Elisa Pasqualoni21, Bernard Bonnotte22, Philippe Ravaud23, Luc Mouthon24 and French Vasculitis Study Group (FVSG)25, 1Internal Medicine, Division of Internal Medicine, Hôpital Cochin, University Paris Descartes, Paris, France, 2Rheumatology, Mount Sinai Hospital, Toronto, Canada, Toronto, ON, Canada, 3Nephrology, Hôpital Européen Georges Pompidou, APHP, Paris, France, 4Pneumology, Hospices Civils de Lyon, Hôpital Louis Pradel, Lyon, France, 5Department of Internal Medicine, Centre Hospitalier de Clermont-Ferrand, Clermont-Ferrand, France, 6National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, 7HP Metz Belle Isle Hospital, Department of Internal Medicine, Metz, France, 8Department of Internal Medicine, Rennes University Hospital, Rennes, France, 9Internal Medicine, Hospices Civils de Lyon, Hôpital Louis Pradel, Lyon, France, 10Nephrology, Centre Hospitalier d'Avignon, Avignon, France, 11Internal medicine, CHR de Valenciennes, Valenciennes, France, 12Internal Medicine, Centre Hospitalier, Niort, France, 13Department of Internal Medicine, Centre Hospitalier Bretagne Atlantique de Vannes, Vannes, France, 14Internal Medicine, Hôpital Cochin, Paris, France, 15Internal Medicine, Centre Hospitalier de Grenoble, Grenoble, France, 16Department of Internal Medicine, Hôpital Claude Huriez, Université Lille II, Lille, France, Paris, France, 17Department of Internal Medicine, Hôpital Henri Mondor, APHP, Creteil, France, 18Internal Medicine Department, Nantes University Hospital, Nantes, France, 19Department of Internal Medicine, Centre Hospitalier d'Annecy, Annecy, France, 20Nephrology, Hôpital Bicbat, APHP, Paris, France, 21Department of Internal Medicine, Hôpital Bicbat, APHP, Paris, France, 22Department of Internal Medicine, Centre Hospitalier de Dijon, Dijon, France, 23Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, 24Internal Medicine, Hopital Cochin, Paris, France, 25Internal Medicine, Hôpital Cochin, Université Paris–Descartes, Paris, France

    Background/Purpose: Once ANCA-associated vasculitis (AAV) remission has been achieved with CS and cyclophosphamide (CYC), maintenance therapy usually relies on azathioprine (AZA) or methotrexate. However, 18-…
  • Abstract Number: 1654 • 2012 ACR/ARHP Annual Meeting

    Primary Endpoint Failure in the Rituximab in ANCA-Associated Vasculitis Trial

    Eli Miloslavsky1, Ulrich Specks2, John H. Stone3 and RAVE/ITN Research Group4, 1Division of Rheumatology, Massachusetts General Hopsital, Boston, MA, 2Mayo Clinic, Rochester, MN, 3Rheumatology, Massachusetts General Hospital, Boston, MA, 4Bethesda, MD

    Primary Endpoint Failure in the Rituximab in ANCA-associated Vasculitis TrialBackground/Purpose: The RAVE trial demonstrated that rituximab (RTX) is non-inferior to cyclophosphamide (CYC) for remission induction…
  • « Previous Page
  • 1
  • …
  • 18
  • 19
  • 20
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology